[Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides].
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental; D003981:Diazoxide / Q000494:pharmacology; D004285:Dogs; D004336:Drug Antagonism; D004357:Drug Synergism; D005947:Glucose / Q000494:pharmacology; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000032:analysis / Q000187:drug effects; D051379:Mice; D009929:Organ Size; D010179:Pancreas / Q000502:physiology*; D010180:Pancreatectomy; D010477:Perfusion; D051381:Rats; D013449:Sulfonamides / Q000494:pharmacology*; D014044:Tolbutamide / Q000494:pharmacology
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013449:Sulfonamides; D013006:Growth Hormone; D014044:Tolbutamide; D005947:Glucose; D003981:Diazoxide